Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: a systematic review and meta-analysis

Urothelial cancer of the bladder, renal pelvis, ureter and other urinary organs is the ninth most common malignancy worldwide. Advanced stages of the disease including locally advanced or metastatic tumours still remain associated to poor prognosis with an estimate 5-years survival of only 5 –30% making management of this tumour a priority and an open challenge for clinicians and researchers (Torre et al., 2015; Siegel et al., 2018).

Source: Critical Reviews in Oncology Hematology - July 19, 2018 Category: Cancer & Oncology Authors: Vincenzo Di Nunno, Emmanuele De Luca, Consuelo Buttigliero, Marcello Tucci, Francesca Vignani, Lidia Gatto, Clizia Zichi, Andrea Ardizzoni, Massimo Di Maio, Francesco Massari Source Type: research